Development of a Long Acting and Stapled Dual Amylin and Calcitonin Receptor Agonist as Monotherapy and Combination with GLP 1R Agonists for the Treatment of Obesity Bioconjugate Chemistry Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library DualPathway Drugs Drive Smarter Weight Loss Fountain of Youth Does receptor balance matter? Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP 336 on metabolic parameters in preclinical models ScienceDirect CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Pharmacy Phase III REDEFINE trials at #ADA2025 reveal that once weekly CagriSema (semaglutide + cagrilintide) delivers impressive weight loss in adults without diabetes and in those with type 2 #diabetes, alongside favorable